An abstract co-authored by Quantify’s Emilie Toresson Grip, has been accepted for oral presentation at the European Society of Cardiology Heart Failure 2021 Online Congress in June. For this abstract, called “Empagliflozin use versus dipeptidyl peptidase 4 inhibitors reduces risk of cardiovascular and renal disease among type 2 diabetes patients in routine care in Europe and Israel: EMPRISE study results”, the Quantify team has provided RWE results on Swedish and Finnish data which have been meta-analyzed together with results from Germany, Spain and Israel.
Key findings include significant risk reductions in cardiovascular and renal disease outcomes comparing empagliflozin with DPP-4 use among patients with T2DM.
#heartfailure2021 #RWE #RWD #type2diabetes #T2DM